ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00388778
Recruitment Status : Unknown
Verified January 2008 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : October 17, 2006
Last Update Posted : January 23, 2008
Sponsor:
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:
The purpose of this study is to compare the safety and efficacy of twice daily subantimicrobial dose doxycycline 20mg with daily doxycycline 100mg in treatment of mild and moderate Acne.

Condition or disease Intervention/treatment Phase
Acne Inflammation Drug: Doxycycline Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne
Study Start Date : October 2005
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Acne

Exclusion Criteria:

  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00388778


Contacts
Contact: Parviz Toossi, M.D. 98-21-22744392 src@sbmu.ac.ir

Locations
Iran, Islamic Republic of
Skin Research Center, Shaheed Beheshti Medical University Recruiting
Tehran, Iran, Islamic Republic of, 19899
Contact: Parviz Toossi, M.D.    98-21-22744392    src@sbmu.ac.ir   
Principal Investigator: Parviz Toossi, M.D.         
Sub-Investigator: Nahid Mohtasham, MD         
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Investigators
Principal Investigator: Parviz Toossi, M.D. Shahid Beheshti University of Medical Sciences

ClinicalTrials.gov Identifier: NCT00388778     History of Changes
Other Study ID Numbers: src-pts-964
First Posted: October 17, 2006    Key Record Dates
Last Update Posted: January 23, 2008
Last Verified: January 2008

Additional relevant MeSH terms:
Inflammation
Pathologic Processes
Doxycycline
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents